SARS-CoV-2/Influenza A/B RT-PCR NEW (CE) | V440-100FRT

SARS-CoV-2/Influenza A/B RT-PCR NEW | V440-100FRT is available for delivery

Description:

General information: RT PCR kit for detection of SARS-CoV2 (COVID19) RNA, Influenza A&B

Target Disease Type: Respiratory Infections

Specific Application: Coronavirus

Storage and Shipping : stock

SARS-CoV-2/Influenza A/B RT-PCR NEW (CE) V440-100FRT DataSheet

INTRODUCTION

Coronaviruses are a large family of ribonucleic acid (RNA) viruses capable of infecting humans and a number of animal species. In humans, coronaviruses may cause a range of illnesses, from the common cold to severe acute respiratory syndrome (SARS).

The novel coronavirus (SARS-CoV-2) is a new strain which has not previously been identified in humans. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known also as 2019 novel coronavirus (2019-nCoV), is a positive-sense single-stranded RNA virus. It is contagious in humans and is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19) that has been designated a Public Health Emergency of International Concern by the World Health Organization (WHO).

Influenza virus infection, one of the most common infectious disease, is a highly contagious airborne disease that causes an acute febrile illness and results in variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza results from infection with 1 of 3 basic types of influenza virus – A, B, or C – which are classified within the family Orthomyxoviridae. These single stranded RNA viruses are structurally and biologically similar but vary antigenically. The most common prevailing influenza A subtypes that infect humans are H1N1 and H3N2.

The symptoms caused from both SARS-CoV-2 and Influenza, contribute to significant loss of workdays, human suffering, mortality, and significant morbidity.

INTENDED USE

SARS-CoV-2/Influenza A/B multiplex Real-TM is Real-Time PCR test for detection and differentiation of the SARS-CoV-2, Influenza A and Influenza B RNA in clinical samples by Real-Time PCR method.

PRINCIPLE OF ASSAY

SARS-CoV-2/Influenza A/B multiplex Real-TM Test is based on three major processes: isolation of virus RNA from specimens, reverse transcription of the RNA, Real Time amplification of the cDNA. The reverse transcription and amplification are performed in a single, one step reaction. Viral detection performed by the polymerase chain reaction (PCR) is based on the amplification of pathogen genome specific region using specific primers and detection via fluorescent dyes. These dyes are linked with probes of oligonucleotides which bind specifically to the amplified product. The real-time PCR monitoring of fluorescence intensities allows the accumulating product detection without reopening of reaction tubes after the PCR run.

SARS-CoV-2/Influenza A/B multiplex Real-TM is a multiplex Real-time PCR assay that detects and identifies the causative agent of the new coronavirus disease (COVID-19) using the E gene and N gene regions specific for SARS-CoV-2 and specific regions for detection and differentiation of the Influenza A and Influenza B.

SARS-CoV-2/Influenza A/B multiplex Real-TM PCR kit is a multiplex Real Time PCR kit with four simultaneous reactions – amplification of Influenza A (FAM channel); amplification of SARS-CoV-2 N gene and E gene (ROX channel); amplification of Influenza B (Cy5 channel) as well as amplification of nucleic acid sequence of the Internal Control-RNA in HEX channel, which allows to exclude inhibition and nucleic acids extraction issues.